SAN DIEGO, April 30 /PRNewswire-FirstCall/ — BioMed Realty Trust, Inc.
(NYSE: BMR) today announced the signing of a new ten-year lease for more than
140,000 square feet at the Pacific Research Center, BioMed’s Newark,
California multi-tenant research campus. DayStar Technologies, Inc.
(Nasdaq: DSTI) will join BioMed’s rapidly expanding roster of tenants at the
Pacific Research Center in the East Bay of San Francisco’s thriving technology
corridor.
DayStar is engaged in the development, manufacturing and marketing of
solar photovoltaic products utilizing its proprietary thin film deposition
technology. DayStar’s Chief Executive Officer, Dr. Stephan DeLuca, said, “The
Pacific Research Center is an ideal location with excellent facilities that
meet our needs as we build our manufacturing capacity.”
Alan Gold, BioMed’s President and Chief Executive Officer, commented, “It
is with great excitement that we welcome Dr. DeLuca and his world-class team
to our Newark campus. This lease further demonstrates our ability to deliver
on our business model of making Pacific Research Center a thriving
multi-tenant research and production campus. DayStar’s long-term addition to
the campus translates into a significant win for both DayStar and BioMed, and
I congratulate our respective teams for bringing this deal to fruition.”
About DayStar Technologies
DayStar Technologies, Inc. is engaged in the development, manufacturing
and marketing of photovoltaic products based upon CIGS thin film semiconductor
technology. For more information, visit the DayStar website at
http://www.daystartech.com.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused
on Providing Real Estate to the Life Science Industry(R). The company’s
tenants primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty Trust owns or has
interests in 69 properties, representing 112 buildings with approximately
10.4 million rentable square feet, including approximately 1.9 million square
feet of development in progress. The company also owns undeveloped land
parcels adjacent to existing properties that it estimates can support up to
1.4 million rentable square feet. The company’s properties are located
predominantly in the major U.S. life science markets of Boston, San Diego, San
Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have
well-established reputations as centers for scientific research. Additional
information is available at http://www.biomedrealty.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants’ financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company’s target markets; risks associated with the availability and terms
of financing and the use of debt to fund acquisitions and developments;
failure to manage effectively the company’s growth and expansion into new
markets, or to complete or integrate acquisitions and developments
successfully; risks and uncertainties affecting property development and
construction; risks associated with downturns in the national and local
economies, increases in interest rates, and volatility in the securities
markets; potential liability for uninsured losses and environmental
contamination; risks associated with the company’s potential failure to
qualify as a REIT under the Internal Revenue Code of 1986, as amended, and
possible adverse changes in tax and environmental laws; and risks associated
with the company’s dependence on key personnel whose continued service is not
guaranteed. For a further list and description of such risks and
uncertainties, see the reports filed by the company with the Securities and
Exchange Commission, including the company’s most recent annual report on Form
10-K and quarterly reports on Form 10-Q. The company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE BioMed Realty Trust, Inc.